CD70 Targeted CAR-T Cells in CD70 Positive Relapsed/Refractory Lymphoma

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

July 15, 2023

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2026

Conditions
Lymphoma
Interventions
BIOLOGICAL

CD70-targeting CAR-T cells

"Dose escalation:~Dose1 (1×10\^6 cells/kg) ,Dose 2(3×10\^6 cells/kg) ,Dose 3 (1×10\^7 cells/kg)~Doseexpansion: RP2D~Drug: Fludarabine~Intravenous fludarabine 25-30 mg/m\^2/day on days 5, -4, and -3.~Drug: Cyclophosphamide~Intravenous cyclophosphamide 300-500 mg/m\^2/day on days -5, -4, and -3."

Trial Locations (1)

Unknown

RECRUITING

China, Beijing

All Listed Sponsors
collaborator

UTC Therapeutics Inc.

INDUSTRY

lead

Chinese PLA General Hospital

OTHER